Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05435001
Other study ID # IGHCEAH-KAEK-139-2022730-35
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 5, 2022
Est. completion date August 1, 2022

Study information

Verified date February 2023
Source Izmir Dr Suat Seren Chest Diseases and Surgery Education and Research Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Obstructive sleep apnea syndrome (OSAS) is a growing health concern affecting up to 60 % of population with cardiovascular disease. Despite the high cardiovascular morbidity and mortality associated with this syndrome, the substantial inconvenience and cost of polysomnography recordings may delay routine evaluation. Polysomnography (PSG) is the gold standard for diagnosis. However, this is a costly and time-consuming examination. Sympathoadrenergic balance obtained from the routine Holter monitoring suggesting the presence of OSAS, can enable patients to be guided and their PSGs to be primarily held.Abnormalities in nocturnal cyclical heart rate (HR) variations have previously been described in sleep-related breathing disorders. Compared with PSG, holter electrocardiogram has the advantages of pervasion, lower cost, no need for overnight hospitalization, greater similarity to normal conditions, and good compliance. The observation of changes in heart rate associated with apneic events has a potential to be used as an alternative technique for identification of subjects with OSAS. In regard to the feasibility of screening OSAS by HRV analysis by holter electrocardiogram monitoring, it has already been reported that a 24-h electrocardiographic monitoring might be useful to diagnose OSAS. It became a more feasible technique to use following the development of a convenient recorder for OSAS screening by analyzing changes in heart rate.


Description:

To find out whether a new algorithm of HRV analysis from holter ECG monitoring can be used as a screening test for the diagnosis of patients with moderate-to-severe risk of obstructive sleep apnea syndrome (OSAS) with an acceptable accuracy.For this, overnight sleep pattern will be investigated in at least 107 individuals by polysomnography and 24-h ambulatory electrocardiography. Heart rate variability sleep apnea risk score (HRV-SARS) will be calculated using HRV analyses. The patients were recruited from individuals referred to our university hospital's sleep center for a polysomnography recording because of clinically suspected OSAS (with at least one of the following obstructive sleep apnea symptoms: witnessed apnea, snoring and/or daytime sleepiness) from May to July 2022. Prospectively 107 patients enrolled in the study according to inclusion and exclusion criteria. Exclusion criteria were permanent or paroxysmal atrial fibrillation, permanent pacemaker, history of other sleep disorders, severe cardiopulmonary disease, severe diabetes mellitus, autonomic dysfunction or major physical or mental ailments. All patients underwent both a full polysomnography recording and ECG Holter monitoring. This new algorithm of HRV analysis from holter ECG monitoring may represent an accurate and inexpensive screening tool in clinically suspected OSAS patients and may help focus resources on those at the highest risk.


Recruitment information / eligibility

Status Completed
Enrollment 107
Est. completion date August 1, 2022
Est. primary completion date July 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - The patients will be recruited from individuals referred to our university hospital's sleep center for a polysomnography recording because of clinically suspected OSAS (with at least one of the following obstructive sleep apnea symptoms: witnessed apnea, snoring and/or daytime sleepiness) Exclusion Criteria: - Permanent or paroxysmal atrial fibrillation, permanent pacemaker, severe cardiopulmonary disease, severe diabetes mellitus, autonomic dysfunction or major physical or mental ailments.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Holter ECG Monitoring
Holter electrocardiogram monitoring will be carried out for 24 h simultaneously with the PSG monitoring using a 2- lead ambulatory electrocardiograph (Fysiologic; kind courtesy: MedTech Company, Amsterdam, Holland). We will calculate the time-domain, frequency-domain and non-linear indices by HRV. Several parameters describing the differences between RR intervals will be calculated: the square root of the mean of the sum of the squares of differences between adjacent normal RR intervals (r-MSSD), SD of NN intervals (SDNN), SD of the averages of NN intervals in all 5-minute segments of the recording (SDANN), and mean of the SD of all NN intervals for all consecutive 5-minute segments of the recording (SDNN index). All variables will be calculated for the 24-hour, daytime (2:00 to 9:00 PM), and nighttime (midnight to 7 AM) periods, and the differences between daytime and nighttime values (D[D/N]) will be computed.

Locations

Country Name City State
Turkey Izmir Dr Suat Seren Chest Disease and Surgery Training and Research Hospital Izmir

Sponsors (2)

Lead Sponsor Collaborator
Izmir Dr Suat Seren Chest Diseases and Surgery Education and Research Hospital Amatis Software and Fysiologic Smart ECG Solutions

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Heart Rate Variability The variation in time intervals between heart beats. HRV analysis (in time, frequency and nonlinear domains) with 2-channel Holter ECG monitoring. 24 hour
See also
  Status Clinical Trial Phase
Recruiting NCT05477719 - Effect of Compression Stockings on the Number of Apneas/Hypopneas Per Hour of Sleep in Patients With Syndrome Obstructive Sleep Apnea/Hypopnea as Compared to no Treatment N/A
Completed NCT04979234 - A Single Centre, Prospective Feasibility Study to Evaluate the Efficacy of an Endoluminal-suturing Device (Endomina) on Severe Obstructive Sleep Apnea Syndrome N/A
Terminated NCT02735694 - Cycloserine in the Treatment of Sleep Apnea Phase 1
Active, not recruiting NCT02470182 - Screening for Sleep Disordered Breathing With Minimally Obtrusive Sensors
Completed NCT02088723 - Testing the Elevation as Sleep Apnea Treatment N/A
Completed NCT01457014 - Sleep Disordered Breathing and Chronic Pain N/A
Completed NCT00860743 - Respiratory and Autonomic Plasticity Following Intermittent Hypoxia Early Phase 1
Completed NCT00976417 - Mechanisms of Action of Adaptive Servoventilation N/A
Active, not recruiting NCT00371293 - The Effects of Obesity and Obstructive Sleep Apnea on Inflammation and Heart Disease N/A
Completed NCT00607893 - Efficacy of Continuous Positive Airway Pressure in Reducing Oxidative Stress in Individuals With Sleep Apnea N/A
Completed NCT00083798 - Family Linkage Study of Obstructive Sleep Apnea (OSA) in Iceland N/A
Completed NCT00070681 - Outcomes of Sleep Disorders in Older Men Phase 3
Completed NCT00089752 - Continuous Positive Airway Pressure to Improve Milder Obstructive Sleep Apnea N/A
Completed NCT00051363 - Apnea Positive Pressure Long-Term Efficacy Study Phase 3
Completed NCT00046670 - Sleep Disordered Breathing, APOE, and Lipid Metabolism N/A
Completed NCT00031239 - Sleep Apnea in Look AHEAD Participants - Ancillary to Look AHEAD N/A
Terminated NCT00006321 - Neurocognitive Function in Snoring Children N/A
Completed NCT00006323 - Neurobehavioral Consequences of Sleep Apnea in Children N/A
Completed NCT00005511 - SCOR in Neurobiology of Sleep--Intermediate Traits for Sleep Apnea N/A
Completed NCT00005275 - Sleep Heart Health Study (SHHS) Data Coordinating Center N/A